Amikacin (Amistar?) is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. Amikacin is effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, urinary tract, bones and joints, central nervous system (including meningiti is) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post vascular surgery). Amikacin is also effective in infections caused by Gentamicin resistant strains of Gram-negative organisms
(in Injection form)
Adults and children: 15mg/kg/day in two equally divided doses (equivalent to 500 mg bid. in adults): use of the 100mg/2ml strength is recommended for children for the accurate measurement of the appropriate dose.
Neonates and premature infants: An initial loading dose of 10mg/kg followed by 15mg/kg/day in two equally divided doses. Life-threatening infections and/or those caused by Pseudomonas: The adult dose may be increased to 500 mg every eight hours but should neither exceed 1.5g/day nor be administered for a period longer than 10 days. A maximum total adult dose of 15g should not be exceeded. Urinary tract infections (other than Pseudomonas infections): 7.5mg/kg/day in two equally divided doses (equivalent to 250 mg bid. in adults)
Manufacturer: Square Pharmaceuticals Ltd.